| Literature DB >> 25095831 |
Darshini Govindasamy1, Jamilah Meghij2, Eyerusalem Kebede Negussi3, Rachel Clare Baggaley3, Nathan Ford3, Katharina Kranzer4.
Abstract
INTRODUCTION: Several approaches have been taken to reduce pre-antiretroviral therapy (ART) losses between HIV testing and ART initiation in low- and middle-income countries, but a systematic assessment of the evidence has not yet been undertaken. The aim of this systematic review is to assess the potential for interventions to improve or facilitate linkage to or retention in pre-ART care and initiation of ART in low- and middle-income settings.Entities:
Keywords: ART eligibility; ART initiation; HIV; antiretroviral therapy; attrition; linkage to care; low- and middle-income countries; pre-ART; retention in care
Mesh:
Substances:
Year: 2014 PMID: 25095831 PMCID: PMC4122816 DOI: 10.7448/IAS.17.1.19032
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Figure 1Selection process for the inclusion of studies.
Description of full-text studies included in the review (listed alphabetically by country)
| Author | Year of study | Country | Setting | ART eligibility criteria | Study design | Intervention and control | Outcome measures | Comments | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Choun [ | 2008–2011 | Cambodia | Phnom Penh, 1 hospital (outpatient), TB patients | 2008–2010: extrapulmonary TB, pulmonary TB and CD4 <350 cells/µL | Before/after study |
|
Proportion of individuals starting ART within 4 or 8 weeks of TB diagnosis Time from TB diagnosis to ART initiation | Age and sex were similar in control and intervention group | ||
| Kundu [ | 2008–2009 | India | Kolkata (urban), 1 tertiary hospital (outpatients), children | Not stated | Before/after study |
| Proportion of children with regular pre-ART follow-up (>6 visits per year) over a 12 months period Proportion of children remaining in care (children with an appointment within the last 6 months) over a 12-month period | Potential for survival bias (3 children died, 6 children were lost to follow-up and 11 children started ART during the first year (control)) | ||
| Hatcher [ | 2009 | Kenya | Nyanza (rural) community-based testing, adults | CD4 cell count <250 cells/µL | Observational study with control group |
| Proportion of individuals enrolled at a clinic 10 months after the positive HIV test | Only individuals who consented to a home visit were assigned the intervention and only individuals who were located received the intervention | ||
| Kohler [ | 2005–2007 | Kenya | Nairobi (urban), 1 outpatient site in a secondary hospital | CD4 cell count <250 cells/µL or WHO stage 3 or 4 | Before/after study |
| Proportion of individuals not yet eligible for ART in care 12 months after enrolment | Age, sex and BMI were similar in the intervention and control group | ||
| MacPherson [ | 2012 | Malawi | Northwest Blantyre (urban), community, adult residents (>16 years of age) | CD4 cell count <350 cells/µL, WHO stage 3 or 4, pregnant or breastfeeding | Cluster randomized trial |
| Proportion of individuals initiated on ART among adult cluster residents | Age and sex was equally balanced in intervention and control clusters | ||
| Weigel [ | 2006–2009 | Malawi | Lilongwe (rural), 1 antenatal care clinic, pregnant women | CD4 cell count <250 cells/µL or WHO stage 3 or 4 | Before/after study |
| Proportion of pregnant women who registered with the ART clinic if they had a CD4 count Proportion of pregnant women who initiated ART among the ones who had registered | Age and CD4 counts similar across years | ||
| Jani [ | 2009–2010 | Mozambique | Maputo and Sofala (rural and per-urban), 4 primary health care clinic, 1 year+ | >15 years: | Before/after study |
| Proportion of individuals who completed a staging visit (receipt of CD4 result and assessment of ART eligibility) within 90 days of testing Proportion of individuals initiating ART if found eligible within 60 days of testing Days between CD4 result and ART initiation for participants found eligible Proportion of individuals initiating ART within 150 days of testing Days between testing and ART initiation | Age and sex were similar in control and intervention group | ||
| Pfeiffer [ | 2004–2007 | Mozambique | Manica and Sofala districts (rural and urban) | Not stated | Observational study with control group |
| Proportion of eligible individuals initiating ART within 90 days Proportion of HIV-positive pregnant women registered for HIV care within 30 days of testing | No data on denominators presented | ||
| Tsague [ | 2008 | Rwanda | National, pregnant women | No stated | Observational study with control group |
| Proportion of HIV-positive pregnant women undergoing a CD4 cell count assessment during pregnancy Proportion of HIV-positive pregnant women enrolling into HIV care and treatment during pregnancy Proportion of eligible HIV-positive pregnant women initiating ART during pregnancy | No outcome verification | ||
| Larson [ | 2010 | South Africa | Johannesburg, 2 mobile clinics, adults | CD4 cell count <200 cells/µL or WHO stage 4 disease | Observational study with control group |
| Proportion of individuals enrolling in HIV care within 8 weeks of HIV testing | Mean age was similar in control and intervention group. There were more women (62%) in the intervention group compared to the control group (55%) | ||
| Faal [ | 2009 | South Africa | Johannesburg (urban), | CD4 cell count <200 cells/µL or WHO stage 4 disease | Individual randomized controlled trial |
| Proportion of individuals reporting for further care within 1 month of HIV testing if not yet eligible (CD4 count >215 cells/µL) Proportion of individuals initiating ART within 3 months of HIV testing if eligible (CD4 count <215 cells/µL) | Baseline variables were distributed equally across the groups | ||
| Fairall [ | 2008–2010 | South Africa | Free State (urban and rural), 31 primary health care clinics, adults (>16 years of age) | Non-pregnant women and men: CD4 cell count <200 cells/µL or WHO stage 4 disease | Cluster randomized control trial |
| Proportion of individuals in HIV care (either pre-ART care or ART care) 6 months of enrolment visit among individuals with CD4 count <350 cell/µL | Age and sex was similar in intervention and control clusters | ||
| Youngleson [ | 2006–2009 | South Africa | Western Cape (urban and rural), 17 antenatal care clinics, pregnant women | CD4 cell count <200 cells/µL or WHO stage 4 disease | Before/after study |
| Proportion of pregnant women who were receiving ART at time of delivery among all women testing HIV positive | No information on age and CD4 count | ||
| Stinson [ | 2005 | South Africa | Cape Town, 3 antenatal care clinics, pregnant women | CD4 cell count <200 cells/µL or WHO stage 4 disease | Observational study with control group |
| Proportion of ART eligible pregnant women initiated on ART during pregnancy | Age was similar in all three groups | ||
| Van der Merwe [ | 2004–2005 | South Africa | Gauteng (urban), 1 hospital, outpatient, antenatal care, pregnant women | CD4 cell count <200 cells/µL or WHO stage 4 disease | Before/after study |
| Time from eligibility assessment to initiation of ART for pregnant women eligible for ART | Age was similar in all three groups | ||
| Burtle [ | 2009–2010 | Swaziland | Lumbombo (rural), 1 secondary hospital, all patients (excluding pregnant women and patients with TB) | CD4 cell count <200 cell/µL or WHO stage 4 | Before/after study |
| Proportion of individuals with documents assessment of eligibility Proportion of ART eligible individuals initiated on ART Days between eligibility assessment and ART initiation | Age and sex were similar in baseline group, during implementation of the intervention, one year after implementing the intervention | ||
| Muhamadi [ | 2009–2010 | Uganda | Iganga (rural), 1 outpatient site in a secondary hospital, 2 primary health care centres, | Not stated | Individual randomized controlled trial |
| Proportion of individuals enrolled in pre-ART care 5 months after testing | Age and sex were similar in control and intervention group | ||
| Wanyenze [ | 2004–2005 | Uganda | Kampala (urban), 1 tertiary hospital, adult inpatients | CD4 cell count <200 cells/µL or WHO stage 4 (but free ARV not widely available) | Individual randomized controlled trial |
| Proportion of individuals attending an HIV clinic within 6 months of testing for those testing positive | Age and sex were similar in control and intervention group | ||
| Topp [ | 2008–2011 | Zambia | Lusaka (urban), 7 primary health care clinics with voluntary testing and counselling, provider initiated testing and counselling was introduced in a step wise approach | CD4 cell count <200 cells/µL or WHO stage 3 or 4 | Observational study with control group |
| Proportion of ART eligible individuals initiated on ART Proportion retained in care at 6 months (including pre-ART and ART care) | Proportion retained in care at 6 months (including pre-ART and ART care) | ||
| Killam [ | 2007–2008 | Zambia | Lusaka, 8 primary health care clinics, antenatal care, pregnant women | CD4 cell count <350 cells/µL or WHO stage 3 or 4 | Before/after study |
| Proportion of ART eligible pregnant women enrolling in ART care within 60 days of testing and before estimated date of delivery Proportion of ART eligible pregnant women initiated on ART within 60 days of testing and before estimated date of delivery | Age was similar in control and intervention group | ||
| Patten [ | 2010–2011 | South Africa | Cape Town, primary healthcare clinic, youth | Before August 2011: CD4 cell count <250 cells/µL or WHO stage 3 or 4 | Before/after study |
| Assessment of ART eligibility Proportion of ART eligible HIV-positive youth initiated on ART Time to ART initiation | Age was similar in control and intervention group. There were significant difference in sex between the “control” and the “intervention” group |
ART=antiretroviral therapy; TB=tuberculosis; IQR=interquartile range; SOC=standard of care; PLHIV=person living with HIV/AIDS; BMI=body mass index; WHO=World Health Organization; INH=isoniazid; ANC=antenatal care; PMTCT=prevention of mother to child transmission, POC=point-of-care; PALSA PLUS=Practical Approach to Lung Health in high-HIV prevalence countries; HAART=highly active antiretroviral therapy; VCT=voluntary counselling and testing; PITC=provider initiated testing and counselling; SD=standard deviation.
Description of conference abstracts included in the review
| Conference | Year of Conference | Author | Year of study | Country | Setting | Group | Study Design | Intervention and Stage | Outcome Measures | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| 19th International AIDS conference | 2012 | Edmonds [ | 2010–2011 | Democratic Republic of Congo | Kinshasa, HIV care and treatment services | Pregnant women | Cluster randomized trial |
| Uptake of HIV treatment and care | Cluster adjusted hazard ratio was 1.39 (95% CI 1.01–1.91) comparing intervention vs. control clinics |
| 20th Conference on Retroviruses and Opportunistic Infections | 2013 | Myer [ | 2011 | South Africa | Cape Town, ANC and ART services | Pregnant women | Sequential before/after design |
| Initiation of ART before delivery | Pre-intervention: 21% (58/271) |
| 19th Conference on Retroviruses and Opportunistic Infections | 2012 | Solomon [ | 2009–2011 | India | Chennai | Injecting drug users | Individual randomized trial |
| Time to ART initiation and number of timely visits to the government centre | Time to initiation: 7 days (intervention) 58 days (control) |
ART=antiretroviral therapy; CI=confidence interval; PMTCT=prevention of mother to child transmission; ANC=antenatal care.
Results (as reported by the authors) of full-text studies included in the review
| Authors | Group | Intervention | Outcome: control group | Outcome: intervention group | Unadjusted relative/risk/hazard/odds ratio | Adjusted relative/risk/hazard/odds ratio | Time to outcome: | Time to outcome: |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Tsague [ | Pregnant women |
| CD4 count assessment: 111/195 (57%) | CD4 count assessment: 547/743 (74%) | Relative risk for CD4 count assessment: 1.3 (1.1–1.4) | |||
| Pfeiffer [ | Unselected and pregnant women |
| Relative risk for registering with HIV care pregnant women: | |||||
| Larson [ | Unselected, tested at a mobile service |
| Linkage to HIV care: 57/122 (47%) | Linkage to HIV care: 117/197 (59%) | Relative risk for linkage to HIV care: | |||
| Wanyenze [ | Inpatients |
| Linkage to HIV care: 39/249 (16%) | Linkage to HIV care: 52/250 (21%) | ||||
| Hatcher [ | Adults community testing campaign |
| HR for enrolment at 10 m | HR for enrolment at 10 m: for men >25 Y: 1.35 (0.97–1.87) | ||||
| Killam [ | Pregnant women |
| HIV care enrolment: 181/716 (25%) | HIV care enrolment: 376/846 (44%) | OR for HIV care enrolment 2.36 (1.90–2.94) | OR for HIV care enrolment 2.06 (1.27–3.34) | ||
|
| ||||||||
| Burtle [ | Unselected |
| Assessment for ART eligibility: 118/200 (59%) | Assessment for ART eligibility: 152/200 (76%) | ||||
| Fairall [ | Unselected |
| Enrolment into pre-ART and ART care: 1229/2022 (85%) | Enrolment into pre-ART and ART care: | Enrolment into pre-ART and ART care: | |||
| Jani [ | Unselected |
| Enrolment into pre-ART and ART care: | Completion of staging: 345/437 (79%) | OR for not completing staging: | OR for not completing staging: | Time to completion of staging: | Time to completion of staging: |
| Faal [ | Unselected |
| Retention in pre-ART care: 52/139 (37%) | Retention in pre-ART care: 31/81 (38%) | Likelihood for retention in pre-ART care: | |||
| Patten [ | Youth |
| Assessment for ART eligibility: 183/272 (67%) | Assessment for ART eligibility: 275/304 (90%) | Relative risk for assessment of ART eligibility 2.4 ( 1.8–3.4) | Time to eligibility assessment: | Time to eligibility assessment: | |
| Muhamadi [ | Unselected |
| Enrolment into pre-ART care: 77/200 (39%) | Enrolment into pre-ART care: 135/200 (68%) | RR for enrolment in pre-ART care at 5 m: 1.8 (1.4–2.1) | |||
| Kundu [ | Children |
| Regular follow-up 81/100 (81%) | Regular follow-up in pre-ART care: 74/80 (93%) | HR for irregular follow-up in pre-ART care: 2.89 (1.09–7.63) | |||
| Kohler [ | Unselected |
| Retention in pre-ART care: 384/610 (63%) | Retention in pre-ART care: 344/414 (83%) | HR for being LTFU in pre-ART care at 12 m: | |||
|
| ||||||||
| Choun [ | Individuals diagnosed with TB |
| ART initiation: 4 weeks: 60/262 (23%) | ART initiation: 4 weeks: 118/190 (62%) | HR for ART initiation at 8 weeks: | HR for ART initiation at 8 weeks: | Time to ART initiation: | Time to ART initiation: |
| Tsague [ | Pregnant women |
| ART initiation: 22/26 (85%) | ART initiation: 105/134 (78%) | Relative risk for ART initiation: | |||
| Weigel [ | Pregnant women |
| Registration with ART clinic: | |||||
| Young-leson [ | Pregnant women |
| ART initiation: 124/1243 (10%) | ART initiation: 122/486 (25%) | ||||
| Stinson [ | Pregnant women |
| ART initiation: 61/130 (47%) | ART initiation: 124/227 (45%) | HR for ART initiation: | |||
| Van der Merwe [ | Pregnant women |
| Time to ART initiation: | Time to ART initiation: | ||||
| Pfeiffer [ | Unselected and pregnant women |
| Relative risk for initiation ART unselected: 1.58 (1.17–2.14) | |||||
| Fairall [ | Unselected |
| Enrolment into pre-ART and ART care: 1229/2022 (85%) | Enrolment into pre-ART and ART care: | Relative risk for enrolment into pre-ART and ART care: | |||
| Burtle [ | Unselected |
| ART initiation: 36/68 (53%) | ART initiation: 96/118 (81%) | ||||
| Topp [ | Unselected |
| ART initiation: 4523/6520 (69%) | ART initiation: 1187/1655 (72%) | OR for ART initiation 1.12 (0.99–1.26) | OR for ART initiation 0.90 (0.82–0.97) | ||
| Jani [ | Unselected |
| ART initiation for eligible patients: 36/93 (39%) | ART initiation for eligible patients: 50/144 (35%) | OR for ART initiation in eligible patients: | OR for ART initiation for eligible patients 2.84 (0.76–10.56) | Time between staging and initiation: | Time between staging and initiation: 6 days (0–22) |
| Faal [ | Unselected |
| Retention in pre-ART/ART care: 74/220 (34%) | Retention in pre-ART/ART care: 59/124 (48%) | Likelihood for retention in pre-ART/ART care: 1.41 (1.08–1.84) | |||
| Patten [ | Youth |
| ART initiation: 22/48 (44%) | ART initiation: 49/99 (50%) | ||||
| Mac-Pherson [ | Community |
| ART initiation: 59/8466 (0.7%) | ART initiation: 180/8194 (2.2%) | Risk ratio for ART initiation: 2.94 (2.10–4.12) | |||
IQR=interquartile range; TB=tuberculosis; HR=hazard ratio; ART=antiretroviral therapy; LTFU=lost to follow-up; OR=odds ratio.
Description of on-going trials
| Title | Status | Country | Subgroup | Intervention | Intervention allocation | Outcomes | Identifier |
|---|---|---|---|---|---|---|---|
| Linking Infectious and Narcology Care in Russia (LINC) [ | Study start date: June 2012 | Russia | Injecting drug users, adults (18+), HIV infected | HIV case management delivered by a peer and point of care CD4 count testing | Individual randomized | Proportion of individuals initiating HIV care within 6 months of enrolment | ClinicalTrials.gov: |
| An intervention to improve antenatal access to CD4 testing an HAART Botswana [ | Study start date: July 2011 | Botswana | Pregnant women, HIV infected | Improved access to CD4 phlebotomy, rapid CD4 result return via SMS messaging sub-Saharan Africa, active follow-up of treatment eligible women, participatory educational sessions for clinic staff, loan program for HIV and CD4 testing supplies | Step-wedge, cluster-randomized | Proportion of eligible pregnant women with CD4 enumeration prior to 26 weeks gestation/prior to delivery | ClinicalTrials.gov: |
| Home-based partner education and testing (HOPE) Study [ | Study start date: May 2013 | Kenya | Pregnant women and their partners | Home-based partner education and HIV testing as part of routine pregnancy services | Individual randomized | Proportion of men linkage to HIV care 6 months post-partum (self-report) | ClinicalTrials.gov: |
| WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS [ | Study start date: January 2013 | Kenya | Adults (18+), HIV infected | Weekly text-messages sub-Saharan Africa | Individual randomized | Proportion of individuals retained in care at 12 months | ClinicalTrials.gov: |
| Testing and linkage to care in injecting drug users in Kenya [ | Study start date: March 2012 | Kenya | Injecting drug users, adults (18+) | POC CD4 count and peer care management | Individual randomized | Proportion of individuals linking to care (data collection done in 5 waves separated by 6 months) | ClinicalTrials.gov: |
| Assisted partner notification to augment HIV treatment and prevention in Kenya (APS) [ | Study start date: June 2012 | Kenya | Sexual partners of HIV-positive individuals | Assisted-partner notification | Individual randomized | Rate of linkage to HIV care of partners within 6 weeks of index case enrolment | ClinicalTrials.gov: |
| Mobile phone technology for prevention of mother-to-child transmission of HIV: acceptability, effectiveness and cost [ | Study start date: May 2011 | Kenya | Pregnant women, HIV infected | Mobile phone technology | Cluster randomized | Proportion of women who successfully complete key PMTCT transition points from antenatal care to 6 weeks postpartum | ClinicalTrials.gov: |
| Integration of HIV care and treatment into antenatal care in Migori district, Kenya [ | Study start date: June 2009 | Kenya | Pregnant women, HIV infected (18+) | Integrated ANC (health care providers within the ANC department will be trained to provide HIV/PMTCT care) | Cluster randomized | Proportion of women enrolled and retained in HIV care and treatment at 6 months and 1 year | ClinicalTrials.gov: |
| Optimizing integrated PMTCT services in rural North-Central Nigeria [ | Study start date: March 2013 | Nigeria | Pregnant women, HIV infected | Integrated PMTCT package: task-shifting to lower cadre, POC CD4 count testing, prominent role for male partners in collaborations with community health workers | Cluster randomized | Proportion of ART eligible pregnant women who initiated ART for the purposes of PMTCT | ClinicalTrials.gov: |
| Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa (RapIT Study) [ | Study start date: October 2012 | South Africa | Non pregnant, adults (18+), HIV infected | ART initiation on the day of HIV testing | Individual randomized | Proportion of individuals alive, in care and virally suppressed at 6 months | ClinicalTrials.gov:NCT0171039 |
| Linkage and Retention: A Randomised Trial to Optimize HIV/TB Care in South Africa (Sizanani) [ | Study start date: August 2010 | South Africa | Adults (18+), HIV infected | Patient navigator and short message service (SMS), sub-Saharan Africa, contacts throughout the follow-up period | Individual randomized | Proportion of ART eligible individuals linked and retained in ART care 9 months after enrolment | ClinicalTrials.gov: |
| The “START” (a Streamlined ART Initiation Strategy) Study (START-ART) [ | Study start date: April 2013 | Uganda | Adults (18+), HIV infected | POC CD4 testing, targeted knowledge transfer, feedback and reporting to clinic and providers | Randomized roll-out to clinics (step-wedge design) | Cumulative incidence of ART initiation in newly treatment eligible HIV-positive patients | ClinicalTrials.gov: |
| The PeerCARE Study (Peer Community-based Assistant in Retention) [ | Study start date: June 2011 | Uganda | Adults (18+), HIV infected | Peer health worker conducting home visit | Individual randomized | Time to ART initiation within 1 year | ClinicalTrials.gov: |
| HIV counselling and testing and linkage to care in Uganda | Study start date: May 2008 | Uganda | Adult (18+) inpatients | More detailed counselling and enhanced linkage to care | Individual randomized(factorial design) | Proportion of individuals receiving of OI prophylaxis and adhering to ART | ClinicalTrials.gov: |
| Enhanced access to HIV care for drug users in San Juan, Puerto Rico [ | Study start date: August 2013 | Puerto Rico | Injecting drug users (18+) | 1) neighbourhood-level HIV testing campaign | Randomized roll-out design (similar to the stepped-wedge design) in 5 neighbourhoods | Proportion of individuals attending HIV care visit at 6 months intervals | ClinicalTrials.gov: |
HAART=highly active antiretroviral therapy; SMS=short message service; ART=antiretroviral therapy; POC=point-of-care.
Quality assessment of published peer reviewed studies
| Author | Study design | Selection | Comparability | Outcome | Randomized controlled trials | Summary |
|---|---|---|---|---|---|---|
| Faal [ | Individual randomized controlled trial | Radom sequence generation – unclear risk of bias | Low risk | |||
| Fairall [ | Cluster randomized control trial | Recruitment – low risk of bias | Low risk | |||
| Muhamadi [ | Individual randomized controlled trial | Radom sequence generation – unclear risk of bias | Unclear risk | |||
| Wanyenze [ | Individual randomized controlled trial | Radom sequence generation – low risk of bias | Low risk | |||
| Hatcher [ | Observational study with control group | 0-0-0 | 1-0 | 0-1-0 | High risk | |
| Pfeiffer [ | Observational study with control group | 1-0-0 | 0-0 | 0-1-0 | Unclear risk | |
| Tsague [ | Observational study with control group | 1-1-1 | 0-0 | 0-1-0 | Unclear risk | |
| Larson [ | Observational study with control group | 1-1-1 | 1-0 | 0-1-0 | Unclear risk | |
| Stinson [ | Observational study with control group | 1-1-1 | 1-0 | 0-1-0 | Unclear risk | |
| Topp [ | Observational study with control group | 1-1-1 | 1-1 | 0-1-0 | Low risk | |
| Choun [ | Before/after study | 1-1-1 | 1-0 | 0-1-1 | Low risk | |
| Kundu [ | Before/after study | 1-0-1 | 0-0 | 0-1-1 | High risk | |
| Kohler [ | Before/after study | 1-1-1 | 1-0 | 0-1-1 | Low risk | |
| Weigel [ | Before/after study | 1-1-1 | 0-0 | 0-0-0 | Unclear risk | |
| Jani [ | Before/after study | 1-1-1 | 1-0 | 0-1-1 | Low risk | |
| Youngleson [ | Before/after study | 1-1-1 | 0-0 | 0-1-0 | Unclear risk | |
| Van der Merwe [ | Before/after study | 1-1-1 | 0-0 | 0-1-0 | Unclear risk | |
| Burtle [ | Before/after study | 1-1-1 | 0-0 | 0-0-0 | High risk | |
| Killam [ | Before/after study | 1-1-1 | 1-0 | 0-1-0 | Low risk | |
| Patten [ | Before/after study | 1-0-1 | 0-0 | 0-0-0 | High risk |
Observational cohort studies:
Selection: studies could score a maximum of 3, the first score for representativeness of the exposed cohort, the second score for the selection of the non-exposed cohort and the third score for ascertainment of exposure.
Comparability: studies could score a maximum of 2, the first score for controlling for important factors, the second score for controlling for any additional factors.
Outcome: studies could score a maximum of 5, the first 2 scores for outcome assessment (a. independent blind assessment, b. record linkage or verification), the second score for time lineated and clear definition of outcome, the last two scores for follow-up (a. complete follow-up, b. subjects with missing outcome assessment unlikely to introduce bias).